Home » Healthcare » Pharmaceuticals » Parkinson’s Disease Therapeutics Market

Parkinson’s Disease Therapeutics Market By Drug Class (Dopamine Agonists, Levodopa/ Caxrbidopa, Anticholinergic Drugs, Monoamine Oxidase B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT) Inhibitors and Adenosine A2 Receptor Antagonist) – Growth, Future Prospects and Competitive Analysis, 2018 – 2026

Price: $4999

Published: | Report ID: 8642 | Report Format : PDF

Market Insights:

Parkinson’s disease (PD) is a progressive nervous system disorder characterized by tremors, rigidity, bradykinesia, and postural instability. It is estimated that the global Parkinson’s disease therapeutics market will show significant market growth over the forecast period from 2018 to 2026. Some key factors that drive PD therapeutics market growth are substantial unmet needs, the projected launch of prominent pipeline drugs (APL-130277, Accordion Pill, P2B-001, ND0612H, etc.), increase in research and development activities for the development of novel PD therapeutics and growing incidence of PD.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

The “Parkinson’s Disease Therapeutics Market – Growth, Future Prospects, and Competitive Analysis, 2018 – 2026” covers a detailed PD therapeutics market from 2016 to 2026. For a comprehensive study of PD therapeutics, this market is segmented into significant drug classes such as dopamine agonists, levodopa/ caxrbidopa, anticholinergic drugs, monoamine oxidase B (MAO-B) inhibitors, catechol-O-methyltransferase (COMT) inhibitors, and adenosine A2 receptor antagonist.

To provide detailed information regarding geographical market trends and future market prospects, the global PD therapeutics market is classified based on regional markets such as North America, Europe, Latin America, Asia Pacific, the Middle East, and Africa. Furthermore, for country-level analysis, the PD therapeutics market is classified into the United States, Canada, Germany, United Kingdom, rest of Europe, Brazil, Mexico, Latin America, Japan, China, rest of Asia Pacific, GCC, and the rest of the Middle East and Africa.

This report includes information regarding the current market trends and future market scenario for PD therapeutics; while presenting statistical data and qualitative information. For a better understanding of the ongoing trends of the PD therapeutics market and future market projections, exhaustive information about the market opportunities, drivers, and challenges in the global PD therapeutics market is included in the report. For further understanding of the R&D study and their impact on future market scenarios, pipeline analysis is included in this report, with detailed analysis and market estimation provided for phase 3 drugs. This report includes sections to provide insight into the critical players involved in the global PD therapeutics market, competitive landscape, and company profiles.

Based on drug class, the global Parkinson’s disease therapeutics market is segmented as follows:

  • Dopamine Agonists
  • Levodopa/ carbidopa
  • Anticholinergic Drugs
  • Monoamine Oxidase B (MAO-B) Inhibitors
  • Catechol-O-Methyltransferase (COMT) Inhibitors
  • Adenosine A2 Receptor Antagonist

Parkinson’s disease (PD) is a nervous system disorder that affects movement; it progresses gradually and sometimes starts with a noticeable tremor. Drugs that increase dopamine levels and control non-motor symptoms are used to manage PD. Currently, dopamine receptor agonists such as pramipexole, ropinirole, Bromocriptine, rotigotine, apomorphine, etc. preferably used in the market alone or combination with levodopa/ carbidopa. Dopamine agonists are not as potent as levodopa and cause fewer dyskinesias. Levodopa, coupled with the decarboxylase inhibitor drug – carbidopa, remains the standard treatment for Parkinson’s disease, which shows fewer adverse effects in short-term use. Newly approved drugs such as nouriast and preregistration phase drugs such as CVT-301 are expected to drive significant market growth during the forecast period. Furthermore, late-stage pipeline drugs such as APL-130277, Accordion Pill, P2B-001, ND0612H, etc., would facilitate market growth in the coming years.

For this study, the global Parkinson’s disease therapeutics market is categorized into:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • U.K.
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • India
    • China
    • Japan
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

According to the World Health Organization (WHO), PD is a universal disorder, with a crude incidence rate of 4.5 to 19 per 100,000 population per year. According to the Parkinson’s Disease Foundation, PD affects about 1 million people in the United States and more than 4 million worldwide. About 60,000 people are diagnosed each year in the United States. Among the considered geographical markets, North America is dominating the PD therapeutics market owing to some key factors, such as a higher target population pool, developed healthcare infrastructure, early diagnosis of disease, extensive research and development for novel drugs, and wide accessibility for novel therapeutics. However, Asia Pacific is set to capture a significant position in coming years because of improving healthcare infrastructure, rising treatment awareness among the general population, and growing incidence of PD. The Asia Pacific is based on an enormous population pool continually growing. Thus there is a corresponding increase in the incidence of PD that would further lead to increased demand for PD therapeutics.

Chapter 1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Phase III-Expert Panel Review
1.3.4. Assumptions

Chapter 2. Executive Summary
2.1. Global Parkinson’s Disease Therapeutics Market Portraiture
2.1.1. Global Parkinson’s Disease Therapeutics Market, by Drug Class, 2017 (US$ Mn)
2.1.2. Global Parkinson’s Disease Therapeutics Market, by Geography, 2017 (Value %)

Chapter 3. Parkinson’s Disease Therapeutics: Market Dynamics and Outlook
3.1. Market Definition and Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Landscape
3.6.1. Competitive Landscape: Global Parkinson’s Disease Therapeutics Market, by Key Players, 2017

Chapter 4. Global Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Dopamine Agonists
4.3. Levodopa/ Carbidopa
4.4. Anticholinergic Drugs
4.5. Monoamine Oxidase B (MAO-B) Inhibitors
4.6. Catechol-O-Methyltransferase (COMT) Inhibitors
4.7. Adenosine A2 Receptor Antagonist
4.8. Pipeline Candidates: Overview
4.8.1. Phase III (Market estimations by 2026)
4.8.1.1. APL-130277 (Cynapsus Therapeutics-Sunovion)
4.8.1.2. Accordion Pill Carbidopa/Levodopa (Intec Pharma)
4.8.1.3. P2B-001 (Pharma Two B)
4.8.1.4. ND0612H (Neuroderm)
4.8.2. Phase II & I (Tabular Information)

Chapter 5. Global Parkinson’s Disease Therapeutics Market, by Geography, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. North America Parkinson’s Disease Therapeutics Market Analysis, 2016 – 2026 (US$ Mn)
5.2.1. North America Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.2.2. North America Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Parkinson’s Disease Therapeutics Market Analysis, 2016 – 2026 (US$ Mn)
5.3.1. Europe Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.3.2. Europe Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Parkinson’s Disease Therapeutics Market Analysis , 2016 – 2026 (US$ Mn)
5.4.1. Asia Pacific Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.4.2. Asia Pacific Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of APAC
5.5. Latin America Parkinson’s Disease Therapeutics Market Analysis , 2016 – 2026 (US$ Mn)
5.5.1. Latin America Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.5.2. Latin America Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa (MEA) Parkinson’s Disease Therapeutics Market Analysis, 2016 – 2026 (US$ Mn)
5.6.1. MEA Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.6.2. MEA Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Abbvie, Inc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. Biogen, Inc.
6.3. Boehringer Ingelheim GmbH
6.4. F. Hoffman-La Roche
6.5. GlaxoSmithKline Plc.
6.6. H. Lundbeck A/S
6.7. Impax Labs, Inc.
6.8. Newron Pharmaceuticals SpA
6.9. Novartis AG
6.10. Orion Corporation
6.11. Teva Pharmaceutical Industries Ltd.
6.12. UCB S.A.

List of Figures

FIG. 1 Parkinson’s Disease Therapeutics: Market Segmentation
FIG. 2 Global Parkinson’s Disease Therapeutics Market, by Drug Class, 2017 (US$ Mn)
FIG. 3 Global Parkinson’s Disease Therapeutics Market, by Geography, 2017 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography, 2017
FIG. 5 Market Competition Landscape, by Key Players, 2017
FIG. 6 Global Dopamine Agonists Market, 2016 – 2026 (US$ Mn)
FIG. 7 Global Levodopa/ Carbidopa Market, 2016 – 2026 (US$ Mn)
FIG. 8 Global Anticholinergic Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 9 Global Monoamine Oxidase B (MAO-B) Inhibitors Market, 2016 – 2026 (US$ Mn)
FIG. 10 Global Catechol-O-Methyltransferase (COMT) Inhibitors Market, 2016 – 2026 (US$ Mn)
FIG. 11 Global Adenosine A2 Receptor Antagonist Market, 2016 – 2026 (US$ Mn)
FIG. 12 U.S. Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 13 Canada Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 14 U.K. Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 15 Germany Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 16 Rest of Europe Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 17 Japan Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 18 China Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 19 Rest of Asia Pacific Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 20 Brazil Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 21 Mexico Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 22 Rest of Latin America Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 23 GCC Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 24 Rest of Middle East and Africa Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)

List of Tables

Table 1 Global Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 2 North America Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 3 North America Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
Table 4 Europe Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 5 Europe Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
Table 6 Asia Pacific Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 7 Asia Pacific Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
Table 8 Latin America Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 9 Latin America Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
Table 10 Middle East and Africa Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 11 Middle East and Africa Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
Table 12 Abbvie,Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 13 Biogen, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 14 Boehringer Ingelheim GmbH: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 15 F. Hoffman-La Roche: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 16 GlaxoSmithKline Plc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 17 H. Lundbeck A/S: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 18 Impax Labs, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 19 Newron Pharmaceuticals SpA: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 20 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 21 Orion Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 22 Teva Pharmaceutical Industries Ltd. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 23 UCB S.A. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Frequently asked questions :

What is the size of Parkinson’s Disease Therapeutics Market?

The market for Parkinson’s Disease Therapeutics Market is expected to reach US$ XX Bn in 2026.

What is the Parkinson’s Disease Therapeutics Market CAGR?

The Parkinson’s Disease Therapeutics Market is expected to see significant CAGR growth over the coming years, at XX%.

What is the Forecast period considered for Parkinson’s Disease Therapeutics Market?

The report is forecasted from 2018-2026.

What is the base year considered for Parkinson’s Disease Therapeutics Market?

The base year of this report is 2021.

Who are the major players in this market?

Abbvie, Inc., Biogen, Inc, Boehringer Ingelheim GmbH, F. Hoffman-La Roche, GlaxoSmithKline Plc., H. Lundbeck A/S, Impax Labs, Inc. are some of the major players in the global market.

Molecular Transport Medium Market

Published:
Report ID: 35092

Angiotensin Converting Enzyme (ACE) Inhibitors Market

Published:
Report ID: 12832

Stroke Management Market

Published:
Report ID: 34872

Pulmonary Embolism Market

Published:
Report ID: 34866

Oral Macromolecular Formulation Market

Published:
Report ID: 34861

Metastatic Melanoma Cancer Diagnostics Market

Published:
Report ID: 34855

Cytomegalovirus (CMV) Infection Treatment Market

Published:
Report ID: 4417

Immune Checkpoint Inhibitors Market

Published:
Report ID: 34697

Intraosseous Devices Market

Published:
Report ID: 7197

Dermatophytic Onychomycosis Therapeutics Market

Published:
Report ID: 34653

Africa Pharmaceutical Market

Published:
Report ID: 34584

Allergic Rhinitis Treatment Market

Published:
Report ID: 34575

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN